Shanghai IxCell Biopharmaceutical Co., Ltd.
PrivateLast Round
Early Funding
Aug 26, 2025
Company Overview
Shanghai IxCell Biopharmaceutical Co., Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was an Early Funding round in August 2025.
Shanghai IxCell Biopharmaceutical Co., Ltd. is a biotechnology company that specializes in the development and industrial production of cell-based drugs, including mesenchymal stem cell, induced pluripotent stem cell, and immune cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai IxCell Biopharmaceutical Co., Ltd. Comparables
Compare Shanghai IxCell Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| uBriGene Biosciences | 83% | |
| Jiangsu Hillgene Biopharmaceutical Co., Ltd. | 83% | |
| OBiO Technology | 81% |
For institutional investors. Book with your work email.
Shanghai IxCell Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 26, 2025 | ||||
| Series B | Mar 12, 2025 | ||||
| Series B Extension | Dec 16, 2022 | ||||
| Series B | Sep 29, 2022 | ||||
| Early Funding | Mar 1, 2021 | ||||
Series A | Nov 13, 2020 |
For institutional investors. Book with your work email.
Shanghai IxCell Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kailian Capital | Early Funding, Series B |
| Shenzhen Dachen Caizhi Venture Capital Management | Series B |
| Guangdong Technology Financial Group | Series B Extension |
| Tasly Capital | Series A |
| SDIC Venture Capital | Series B Extension |
| Zhejiang Huaou Venture Capital | Early Funding, Series A |
| 新丝路金控 | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2025
Raised capital from Kailian Capital and Zhejiang Huaou Venture Capital.
- Mar 12, 2025
Completed a Series B funding round.
For institutional investors. Book with your work email.
Shanghai IxCell Biopharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai IxCell Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai IxCell Biopharmaceutical Co., Ltd. a public or private company?
Shanghai IxCell Biopharmaceutical Co., Ltd. is a private company.
What is the current stock price of Shanghai IxCell Biopharmaceutical Co., Ltd.?
Shanghai IxCell Biopharmaceutical Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Shanghai IxCell Biopharmaceutical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai IxCell Biopharmaceutical Co., Ltd. worth (valuation)?
Valuation information for Shanghai IxCell Biopharmaceutical Co., Ltd. is not publicly available.
Can I buy Shanghai IxCell Biopharmaceutical Co., Ltd. stock?
Shanghai IxCell Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai IxCell Biopharmaceutical Co., Ltd.'s last funding round?
Shanghai IxCell Biopharmaceutical Co., Ltd.'s most recent funding round was Early Funding on August 26, 2025.
Who are the main investors in Shanghai IxCell Biopharmaceutical Co., Ltd.?
Key investors in Shanghai IxCell Biopharmaceutical Co., Ltd. include Kailian Capital, Shenzhen Dachen Caizhi Venture Capital Management, Guangdong Technology Financial Group, Tasly Capital, SDIC Venture Capital.
Will Shanghai IxCell Biopharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai IxCell Biopharmaceutical Co., Ltd..
How can I track Shanghai IxCell Biopharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai IxCell Biopharmaceutical Co., Ltd.'s shares on secondary markets.